IPN60130
Phase 2Small molecule
IPN60130 is one of 8 small molecule programs targeting Fibrodysplasia Ossificans Progressiva. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Fibrodysplasia Ossificans Progressiva
#DrugCompanyPhaseTrials
1Versed
CConrado Roberto Hoffmann Filho
Approved
Andecaliximab
GileadPhase 3
Aristan
NNational Cancer Institute (NCI)
Phase 2
Sohonos
IpsenPhase 2
INCB000928
IncytePhase 2
REGN2477
RegeneronPhase 2
IPN60130
CClementia Pharmaceuticals Inc.
Phase 2
Garetosmab
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IPN60130. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CClementia Pharmaceuticals Inc.